

2008 OCT 22 P 4 05

OFFICE OF THE CLERK
U.S. SECURITIES AND EXCHANGE COMMISSION

Carl Zeiss Meditec AG 07740 Jena

Securities and Exchange Commission
Division of Corporation Finance
Office of International Corporate Finance
450 Fifth Street, N. W.
Washington, D. C. 20549
United States

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52
07745 Jena
Germany

Phone: +49 36 41/ 220-105

Fax: +49 36 41/ 220-117

e-mail: j.brajer@meditec.zeiss.com



Division/Dept.: Corporate Affairs
Your contact: Jens Brajer

Our ref.: JB/Mtr

Date: 2008-09-24

File No. 82-34817

SUPL

Dear Ladies and Gentlemen,

Please find attached the following documents they were released to our shareholders:

Type of document	Date of release
Press release	2008-09-15

Best regards,

Carl Zeiss Meditec AG
i. V.

Jens Brajer
Director Corporate Affairs

PROCESSED
SA OCT 28 2008
THOMSON REUTERS

Lydia Fischer
Assistant Corporate Affairs

deu/10/23

Chairman of the Supervisory Board:
Dr. Markus Guthoff

Address of Record:
Goeschwitzer Str. 51-52
07745 Jena, Germany
Tel.: +49 36 41 220-0

Commercial Register:
Local Court Jena HRB 205623
VAT-ID. No. DE 811 922 737
WEEE-Reg.-Nr. DE55298748

Dresdner Bank Jena
Account: 343424200 (BIC 820 800 00)
S.W.I.F.T.- Code: DRES DE FF 825
IBAN: DE1282080000343424200

Board of Management:
Dr. Michael Kaschke, President and CEO
Ulrich Krauss,
Bernd Hirsch
Dr. Ludwin Monz

Address for Delivery:
Carl Zeiss Meditec AG
Carl-Zeiss-Promenade 10
07745 Jena, Germany

Deutsche Bank Jena
Account: 624536900 (BIC 820 700 00)
S.W.I.F.T.-Code: DEUT DE 8E
IBAN: DE90820700000624536900

Commerzbank Jena
Account: 258072800 (BIC 820 400 00)
S.W.I.F.T.- Code: COBADEFFXXX
IBAN: DE3182040000258072800

RECEIVED

2008 OCT 22 PM 4:07

ZEISS CARL ZEISS MEDITEC



Carl Zeiss Meditec reorganises management of its strategic business units

**Dr. Ludwin Monz takes over Ophthalmic Systems business unit –
Thomas Simmerer new Head of Neuro/ENT Surgery – James L. Taylor
to leave company and assume a consulting role for CZM**

(Jena, 15 September 2008) Medical technology supplier Carl Zeiss Meditec AG, listed in the TecDAX at the German Stock Exchange (ISIN DE0005313704), is expanding the management of its strategic business units. In doing so the company is creating a further important prerequisite for accelerating its expansion course as announced.

James L. Taylor, hitherto Head of the SBU Ophthalmic Systems, will be leaving the company for personal reasons on 30 September 2008. He will continue to be available to Carl Zeiss Meditec as a consultant in strategic, organisational and clinical application-related matters. The regional focus will be placed on the US market. With effect from 1 October 2008, Board Member Dr. Ludwig Monz has been appointed new Head of the SBU Ophthalmic Systems. He was previously responsible for the SBU Neuro/ENT Surgery, which he successfully set on a profitable expansion course. In his new position Dr. Ludwig Monz intends to further expand the innovative power of Ophthalmic Systems, which includes diagnostic and therapeutic systems for ophthalmology, thereby securing the long-term success of this business unit.

Dr. Ludwig Monz is concurrently handing over the helm of Neuro/ENT Surgery to Thomas Simmerer. Thomas Simmerer joined Carl Zeiss Meditec on 1 September 2008. He has gained broad experience in medical technology, of late at Dräger Medical AG & Co. KG, where he held various managerial positions, most recently serving as head of a business unit.

The management of the SBU Surgical Ophthalmology is to remain in the hands of Dr. Christian Müller. He has been responsible for this unit since

Press Release



2006. During this time he has actively and successfully promoted its expansion and implemented the integration of Acri.Tec.

"Mr Taylor has been instrumental in making Carl Zeiss Meditec one of the leading companies in the field of ophthalmology in the past few years. My sincere thanks are due to him for his effort and dedication. I am pleased that Mr Taylor will continue to support us in the role of independent consultant and that we will be able to draw on his experience in future. Furthermore, I am convinced that we are ideally set with our current team to accelerate the proposed realisation of growth potential of Carl Zeiss Meditec," says Dr. Michael Kaschke, President and CEO of Carl Zeiss Meditec.

Press Release



Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's leading medical technology companies. This market position is based on over 160 years of experience in optical innovation.

The company has two primary areas of activity: In the field of **ophthalmology** Carl Zeiss Meditec offers integrated solutions for treating the four main eye diseases: vision defects (refraction), cataracts, glaucoma and retinal disorders. The company's system solutions are employed in all phases of the disease management, from diagnosis to treatment and follow-up. Carl Zeiss Meditec has always applied its technological expertise to product innovations. These innovations range from basic systems such as slit lamps and fundus cameras to standard setting diagnostic systems such as the Humphrey® Field Analyser, the Cirrus HD-OCT™ and the IOLMaster®, through to the surgical microscopes and innovative treatment systems in refractive laser surgery. The product portfolio in ophthalmic surgery is rounded off by intraocular lenses and consumables.

In the field of **neuro and ENT surgery**, Carl Zeiss Meditec is the world's leading provider of surgical microscopes and microsurgical visualisation solutions for a very broad range of applications, such as tumor and vascular surgery in the head region and/or spinal surgery. The most recent example of the innovative performance in the area of microsurgery is the OPMI Pentero® visualisation system, which allows efficient and ergonomic patient treatment. Carl Zeiss Meditec will systematically expand its product range in this area and become a solution provider in neuro and ENT surgery as well.

Carl Zeiss Meditec's medical technology portfolio is rounded off by visualisation systems for doctors in private practice and promising future technologies such as intraoperative radiation therapy, which allows the targeted treatment of breast cancer and brain cancer directly during surgery.

Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany (Carl Zeiss Surgical GmbH, Carl Zeiss Meditec Vertriebsgesellschaft mbH, Acri.Tec AG and Carl Zeiss Medical Software GmbH), the USA (Carl Zeiss Meditec, Inc., Dublin), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl Zeiss Meditec Iberia S.A., Madrid) and France (Carl Zeiss Meditec S.A.S., La Rochelle, and Carl Zeiss Meditec France SAS, Le Pecq).

Thirty-five percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss, one of the world's leading international groups engaged in the optical and opto-electronics industry.

Contact

Eva Sesselmann
Director Corporate Communications
Goeschwitzer Straße 51-52

Press Release

15 September 2008

Page 4 of 4



CARL ZEISS MEDITEC

07745 Jena, Germany

Telephone: +49 (0) 36 41 - 2 20 - 331

Telefax: +49 (0) 36 41 - 2 20 - 112

E-Mail: e.sesselmann@meditec.zeiss.com

Web: <http://www.meditec.zeiss.com>

Press Release

END